Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients

被引:14
|
作者
Pease, Daniel F. [1 ]
Ross, Julie A. [2 ]
Poynter, Jenny N. [2 ]
Nguyen, Phuong L. [3 ]
Hirsch, Betsy [4 ]
Cioc, Adina [5 ]
Roesler, Michelle A. [2 ,6 ]
Warlick, Erica D. [7 ]
机构
[1] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55454 USA
[3] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[5] VA Med Ctr, Hematopathol, Minneapolis, MN 55417 USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
关键词
Myelodysplastic syndromes; Hematologic malignancies; Drug therapy; Bone marrow transplantation; STEM-CELL TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; RETROSPECTIVE MULTICENTER ANALYSIS; CONVENTIONAL CARE REGIMENS; IDENTICAL SIBLING DONORS; ACUTE MYELOID-LEUKEMIA; DECISION-ANALYSIS; OLDER PATIENTS; PHASE-III; THERAPY;
D O I
10.1016/j.canep.2015.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The heterogeneous nature of myelodysplastic syndromes (MDS) complicates therapeutic decision making, particularly for newly diagnosed disease. Factors impacting the treatment plan in this early period of disease course are poorly defined. This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age. Methods: The adults in Minnesota with myelodysplastic syndromes (AIMMS) database was utilized in this statewide, prospective population-based study conducted by the University of Minnesota (UMN), Mayo Clinic, and Minnesota Department of Health. Adult (age 20+ years) cases of MDS newly diagnosed starting in April 2010 were invited to participate. This analysis includes patients enrolled during the first study year with 1-year follow-up data. Treatment choices (supportive, active, and transplant) were stratified by the international prognostic scoring system (IPSS) and the revised-IPSS (IPSS-R), then separated into groups by location of care and age (<65 or 65+ years). Academic-based care was any contact with the UMN and Mayo Clinic; community-based care was all other clinical sites. Results: Stratification by IPSS and IPSS-R showed supportive care decreased and active care increased with advancing risk categories (p < 0.0001). Comparing treatment setting, community-based care had 77% supportive and 23% active treatment; academic-based care was 36% supportive, 41% active, and 23% transplant (p < 0.0001). By age groups, patients < 65 years with intermediate, high, or very high risk disease by IPSS-R received 97% active care/transplant, compared to only 52% of patients age 65+. Conclusions: Younger patients and those treated at academic centers had a more aggressive treatment approach. Whether these treatment differences convey improved disease control and mortality, and therefore should be extended more frequently to older and community-based patients, is the subject of ongoing prospective study. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [41] Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
    Mosquera Orgueira, Adrian
    Perez Encinas, Manuel
    Diaz Varela, Nicolas A.
    Mora, Elvira
    Diaz-Beya, Marina
    Julia Montoro, Maria
    Pomares, Helena
    Ramos, Fernando
    Tormo, Mar
    Jerez, Andres
    Nomdedeu, Josep F.
    De Miguel Sanchez, Carlos
    Leonor, Arenillas
    Carcel, Paula
    Cedena Romero, Maria Teresa
    Xicoy, Blanca
    Rivero, Eugenia
    del Orbe Barreto, Rafael Andres
    Diez-Campelo, Maria
    Benlloch, Luis E.
    Crucitti, Davide
    Valcarcel, David
    BLOOD, 2022, 140 : 1132 - 1134
  • [42] Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience
    Al-Kali, Aref
    He, Rong
    Patnaik, Mrinal M.
    Viswanatha, David S.
    Greipp, Patricia T.
    Zblewski, Darci
    Elliott, Michelle
    Gangat, Naseema
    Tefferi, Ayalew
    Litzow, Mark R.
    Nguyen, Phuong L.
    BLOOD, 2016, 128 (22)
  • [43] Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)
    Al-Issa, Karam
    Madanat, Yazan F.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Abuhadra, Nour
    Makhoul, Ahed
    Awada, Hassan
    Asad, Mohammad Fahad B.
    Goyal, Abhinav
    Advani, Anjali S.
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [44] Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
    Komrokji, Rami S.
    Kulasekararaj, Austin G.
    Al Ali, Najla H.
    Kordasti, Shahram Y.
    Bart-smith, Emily
    Benjamin, Craig
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan
    Mufti, Ghulam J.
    Epling-Burnette, Pearlie K.
    BLOOD, 2013, 122 (21)
  • [45] Presence of interstitial lung diseases (ILD) in patients diagnosed with myelodysplastic syndromes (MDS): Mayo Clinic experience.
    Nanah, Rama
    Zblewski, Darci
    Patnaik, Mrinal M.
    Begna, Kebede
    Ketterling, Rhett P.
    Iyer, Vivek
    Hogan, William J.
    Litzow, Mark Robert
    Ai-Kali, Aref
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [47] HYPERFERRITINEMIA IS ASSOCIATED WITH IMPAIRED SURVIVAL IN PATIENTS DIAGNOSED WITH MYELODYSPLASTIC SYNDROMES RESULTS FROM THE FIRST POLISH MDS REGISTRY
    Waszczuk-Gajda, A.
    Dwilewicz-Trojaczek, J.
    Madry, K.
    Drozd-Sokolowska, J.
    Stella-Holowiecka, B.
    Machowicz, R.
    Mital, A.
    Obara, A.
    Szmigielska-Kaplon, A.
    Sikorska, A.
    Kolkowska-Lesniak, A.
    Subocz, E.
    Mendrek, W.
    Szczepanska, M.
    Biedron, M.
    Jachalska, A.
    Wasilewska, E.
    Wojciechowska, M.
    Guzicka-Kazmierczak, R.
    Wiater, E.
    Kopacz, A.
    Katinas, K.
    Kruger, W.
    Dawidowska, A.
    Zawirska, D.
    Salamanczuk, Z.
    Swiderska, A.
    Gornik, S.
    Sedzimirska, M.
    Soroka-Wojtaszko, M.
    Nowicki, A.
    Jedrzejczak, W. W.
    HAEMATOLOGICA, 2015, 100 : 722 - 722
  • [48] Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Lhotska, Halka
    Svobodova, Karla
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Krejcik, Zdenek
    Belickova, Monika
    Siskova, Magda
    Jonasova, Anna
    Neuwirtova, Radana
    Zmolikova, Jana
    Cermak, Jaroslav
    BLOOD, 2014, 124 (21)
  • [49] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [50] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092